4//SEC Filing
Clague Laura 4
Accession 0001209191-22-028707
CIK 0001438533other
Filed
May 11, 8:00 PM ET
Accepted
May 12, 8:45 PM ET
Size
7.1 KB
Accession
0001209191-22-028707
Insider Transaction Report
Form 4
Clague Laura
Chief Financial Officer
Transactions
- Sale
Common Stock
2022-05-10$21.51/sh−825$17,746→ 37,030 total - Sale
Common Stock
2022-05-11$21.51/sh−1,375$29,576→ 35,655 total
Footnotes (2)
- [F1]The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.51 to $21.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001388773
Filing Metadata
- Form type
- 4
- Filed
- May 11, 8:00 PM ET
- Accepted
- May 12, 8:45 PM ET
- Size
- 7.1 KB